Supplementary information for:

Stereoselective semi-synthesis of the neuroprotective natural product, serofendic acid

Dimitri Perusse¹ and Michael J. Smanski^{1*}

Correspondence to: smanski@umn.edu

This PDF file includes:

Table S1

Materials and Methods

Figs. S1 to S67

Captions for Data S1 to S67

¹Department of Biochemistry, Molecular Biology, and Biophysics and BioTechnology Institute. University of Minnesota – Twin Cities, Saint Paul, MN, 55108, USA

Molecule #	Name in article	IUPAC name
1A	Serofendic acid A	<i>ent</i> -(15S,16R,S)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
1B	Serofendic acid B	<i>ent</i> -(15S,16R,R)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
S2	Methyl (15S)-15-hydroxy- <i>ent</i> -atis-16-en-19- oate	Methyl <i>ent-</i> (15R)-15-hydroxyatis-16-en- 19-oate
S3	Methyl (15S,16R)-15,17-dihydroxy- <i>ent-</i> atisan-19-oate	Methyl <i>ent-</i> (15R,16S)-15,17- dihydroxyatisan-19-oate
S4	Methyl (16R)-17-hydroxy-15-oxo- <i>ent-</i> atisan-19-oate	Methyl <i>ent-</i> (16S)-17-hydroxy-15- oxoatisan-19-oate
3	Methyl (15R,16R)-15,17-dihydroxy- <i>ent-</i> atisan-19-oate	Methyl <i>ent</i> -(15S,16S)-15,17- dihydroxyatisan-19-oate
S8	Methyl (16S)-17-methylsulfenyl-15-oxo- <i>ent</i> -atisan-19-oate	Methyl <i>ent-</i> (16R)-17-methylsulfenyl-15- oxoatisan-19-oate
S 9	Methyl (16R)-17-methylsulfenyl-15-oxo- <i>ent</i> -atisan-19-oate	Methyl <i>ent-</i> (16S)-17-methylsulfenyl-15- oxoatisan-19-oate
4	Methyl (15R,16S)-15-hydroxy-17- methylsulfenyl- <i>ent</i> -atisan-19-oate	Methyl <i>ent</i> -(15S,16R)-15-hydroxy-17- methylsulfenylatisan-19-oate
S10	Methyl (15S,16R)-15-hydroxy-17- methylsulfenyl- <i>ent</i> -atisan-19-oate	Methyl <i>ent</i> -(15R,16S)-15-hydroxy-17- methylsulfenylatisan-19-oate
S11	Methyl (15S,16S)-15-hydroxy-17- methylsulfenyl- <i>ent</i> -atisan-19-oate	Methyl <i>ent</i> -(15R,16R)-15-hydroxy-17- methylsulfenylatisan-19-oate
S12	Methyl (15R,16R)-15-hydroxy-17- methylsulfenyl- <i>ent</i> -atisan-19-oate	Methyl <i>ent</i> -(15S,16S)-15-hydroxy-17- methylsulfenylatisan-19-oate
7	(16S)-17-methylsulfenyl-15-oxo- <i>ent</i> -atisan- 19-oic acid	<i>ent</i> -(16R)-17-methylsulfenyl-15-oxo- atisan-19-oic acid
8	(16R)-17-methylsulfenyl-15-oxo- <i>ent</i> -atisan- 19-oic acid	<i>ent</i> -(16S)-17-methylsulfenyl-15-oxo- atisan-19-oic acid

Table S1: Summary of the molecules that have a name that differs from the IUPAC convention

_

9	(15R,16S)-15-hydroxy-17-methylsulfenyl- <i>ent</i> -atisan-19-oic acid	<i>ent</i> -(15S,16R)-15-hydroxy-17- methylsulfenylatisan-19-oic acid
10	(15S,16S)-15-hydroxy-17-methylsulfenyl- <i>ent</i> -atisan-19-oic acid	<i>ent-</i> (15R,16R)-15-hydroxy-17- methylsulfenylatisan-19-oic acid
11	(15S,16R)-15-hydroxy-17-methylsulfenyl- <i>ent</i> -atisan-19-oic acid	<i>ent-</i> (15R,16S)-methyl-15-hydroxy-17- methylsulfenylatisan-19-oic acid
12	(15R,16R)-15-hydroxy-17-methylsulfenyl- <i>ent</i> -atisan-19-oic acid	<i>ent</i> -(15S,16S)-15-hydroxy-17- methylsulfenylatisan-19-oic acid
13A	(16S,R)-17-methylsulfinyl-15-oxo <i>-ent-</i> atisan-19-oic acid	<i>ent-</i> (16R,S)-17-methylsulfinyl-15-oxo- atisan-19-oic acid
13B	(16S,S)-17-methylsulfinyl-15-oxo- <i>ent-</i> atisan-19-oic acid	<i>ent-</i> (16R,R)-17-methylsulfinyl-15-oxo- atisan-19-oic acid
14A	(16R,R)-17-methylsulfinyl-15-oxo- <i>ent-</i> atisan-19-oic acid	<i>ent-</i> (16S,S)-17-methylsulfinyl-15-oxo- atisan-19-oic acid
14B	(16R,S)-17-methylsulfinyl-15-oxo- <i>ent-</i> atisan-19-oic acid	<i>ent-</i> (16S,R)-17-methylsulfinyl-15-oxo- atisan-19-oic acid
15A	(15S,16S,R)-15-hydroxy-17-methylsulfinyl- <i>ent</i> -atisan-19-oic acid	<i>ent-</i> (15R,16R,S)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
15B	(15S,16S,S)-15-hydroxy-17-methylsulfinyl- <i>ent</i> -atisan-19-oic acid	<i>ent-</i> (15R,16R,R)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
16A	(15R,16R,R)-15-hydroxy-17-methylsulfinyl- <i>ent</i> -atisan-19-oic acid	ent-(15S,16S,S)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
16B	(15R,16R,S)-15-hydroxy-17-methylsulfinyl- <i>ent</i> -atisan-19-oic acid	<i>ent-</i> (15S,16S,R)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
17A	(15S,16R,R)-15-hydroxy-17-methylsulfinyl- <i>ent</i> -atisan-19-oic acid	<i>ent</i> -(15R,16S,S)-15-hydroxy-17- methylsulfinylatisan-19-oic acid
17B	(15S,16R,S)-15-hydroxy-17-methylsulfinyl- <i>ent</i> -atisan-19-oic acid	<i>ent-</i> (15R,16S,R)-15-hydroxy-17- methylsulfinylatisan-19-oic acid

Material and Methods

All chemicals and reagents were purchased from commercial sources and used directly without further purification. All non-aqueous reactions were performed under an atmosphere of argon in flamedried glassware. Reaction progress was monitored by thin-layer chromatography (TLC) using silica gel plates (silica gel 60 F254). Eluted TLC plates were visualized with UV light (254 nm) and dyed using ethanol acidified with sulfuric acid (5% v/v). Compounds were purified either by flash silica gel (230-400 mesh) column chromatography or by Büchi C-700 chromatograph apparatus with 4 g or 25 g Büchi FlashPure EcoFlex cartridges. NMR experiments were performed on Bruker Advance III 500 MHz (Broadband Observe SmartProbe) or Bruker Advance 700 MHz (5-mm triple resonance cryoprobe) spectrometers. Chemical shifts were reported as ppm relative to either chloroform-d (7.26 ppm for ¹H, 77.16 ppm for ¹³C) or methanol-d₄ (3.31 ppm for ¹H and 49.00 ppm for ¹³C). ¹H constant coupling (*J*) are expressed in hertz (Hz), and multiplicity is described as follows: s = singlet, d = doublet, d_{app} = appearing doublet, t = triplet, br = broad, m = multiplet. Compounds were analyzed by HR-ESI-MS (ThermoScientific, Q Exactive, Quadrupole, Orbitrap, Heated-Electrospray Ionization probe source (HESI-II)).

Trace elements solution preparation

A mixture of zinc (II) chloride (40 mg), iron (III) chloride hexahydrate (200 mg), copper (II) chloride dihydrate (10 mg), manganese (II) chloride tetrahydrate (10 mg), sodium tetraborate decahydrate (10 mg) and ammonium molybdate tetrahydrate (10 mg) were dissolved in Milli-Q water (up to 1L). The solution was autoclaved at 120°C for 30 min.

R2YE medium preparation

A first solution was prepared. For that, a mixture of sucrose (103 g), potassium sulfate (0.25 g), magnesium chloride hexahydrate (10.12 g), glucose (10 g), casamino acids (0.1 g), yeast extract (5 g) and TES buffer (5.73 g) were diluted in Milli-Q water (up to 950 mL). This solution was autoclaved at 120°C for 30 min.

To 4.75 mL of this sterile solution, once cooled down to room temperature, were added trace elements solution (10 μ L), sodium hydroxide 1 M (25 μ L), a solution of monopotassium phosphate 0.5% (m/v) (50 μ L), a solution of proline 20% (m/v) (75 μ L) and calcium chloride 1M (100 μ L).

ISM3 medium preparation

A mixture of yeast extract (7.5 g), malt extract (5 g), magnesium sulfate heptahydrate (0.5 g), iron (III) chloride hexahydrate (0.15g) and glucose (10 g) were dissolved in Milli-Q water (up to 500 mL). The mixture was autoclaved at 120°C for 30 min.

Synthesis of 15-hydroxy-17-methylsulfenyl-*ent*-atisan-19-oic acids (9-12) using different reducing reagents

Procedure for sodium borohydride (Hsu, et al.)

The synthesis of **9-12** was performed as reported in literature (Hsu, et al., in revision). Briefly, to a solution of sodium borohydride (185.2 mg, 4.90 mmol) in ethanol (200 proof, 15 mL) cooled down to 0° C was added dropwise an epimeric mixture of **7** and **8** (178.5 mg, 0.49 mmol) in ethanol (200 proof, 5.0 mL). After 25 min of stirring at 0° C, hydrochloric acid 1M was added to mixture until the bubbling stop. The solution was then evaporated and the residue was dissolved in ethyl acetate (20 mL), washed with brine (10 mL), dried over anhydrous magnesium sulfate and concentrated. Column chromatography using an *n*-hexane to *n*-hexane/ethyl acetate (7:3 v/v) gradient allowed the isolation of a mixture composed of **9** and **10**, **11** (19.5 mg, white powder, 11%) and **12** (69.8 mg, white powder, 39%). Semi preparative HPLC purification on the latter mixture using the gradient 0 – 1 min, 95% solvent A; 1 – 3 min, 95% solvent B; 3 – 7 min, 95% solvent B; 7 – 9 min, 95% solvent A; 9 – 18 min, 95% solvent A, allowed the separation of **9** (17.8 mg, white powder, 10%) from **10** (53.0 mg, white powder, 30%). For ¹H and ¹³C NMR data of **9-12**, see **Supplementary Fig. S28-39**. HRESIMS: *m/z* calculated for C₂₁H₂₉O₃S⁻ [M-H]⁻ 365.2156 (100%), [M+2-H]⁻ 367.2114 (4%), **9**: found 365.2155 (100%), 367.2113 (4%), **10**: found 365.2155 (100%), 367.2113 (4%), **11**: found 365.2155 (100%), 367.2113 (4%), **12**: found 365.2155 (100%), 367.2113 (4%).

Procedure for borane-THF complex in THF 1 M, L-selectride in THF 1M and disiamylborane in THF 0.5 M

To an epimeric mixture of sulfides **7** and **8** (2.0 mg, 5.5 μ mol) in THF (50 μ L) cooled down to 0°C was added a solution of reducing reagent (10 eq, 54.9 μ mol). The reaction medium was stirring at 0°C for 1 h. The medium was then quenched with the addition of methanol (40 μ L) followed by a solution of HCl 10% (20 μ L). 10 μ L of medium was collected, diluted with methanol (up to 1 mL) and then injected in LCMS for analysis.

Procedure for sodium triacetoxyborohydride with acetic acid 1,2

To a solution of sodium triacetoxyborohydride (5.8 mg, 27.4 μ mol) in acetonitrile (800 μ L) was added acetic acid (2.0 μ L, 54.9 μ mol). The mixture was cooled down to 0°C and then an epimeric mixture of sulfides **7** and **8** (2.0 mg, 5.5 μ mol) in acetonitrile (800 μ L) was added. The mixture was stirred at 0°C for 4 h and then was quenched by adding methanol (40 μ L) and a solution of HCl 10% (20 μ L). 10 μ L of medium was collected, diluted with methanol (up to 1 mL) and then injected in LCMS for analysis.

Procedure for sodium triacetoxyborohydride without acetic acid

To a solution of sodium triacetoxyborohydride (5.8 mg, 27.4 μ L, 5eq. or 11.6 mg, 54.9 μ mol, 10 eq.) cooled down to 0°C an epimeric mixture of sulfides **7** and **8** (2.0 mg, 5.5 μ mol) in acetonitrile (800 μ L) was added. The mixture was stirred at 0°C for 4 h and then was quenched by adding methanol (40 μ L) and a solution of HCl 10% (20 μ L). 10 μ L of medium was collected, diluted with methanol (up to 1 mL) and then injected in LCMS for analysis.

Procedure for pinacolborane activated by alkoxide

To a solution of pinacolborane (7.0 mg, 54.9 μ mol) in THF (100 μ L) was added a solution of potassium *tert*butoxide (6.2 mg, 54.9 μ mol) in THF (100 μ L). After stirring at room temperature for 10 min, an epimeric mixture of sulfides **7** and **8** (4.0 mg, 11.0 μ mol) in solution in THF (100 μ L) was added to the medium. The reaction medium was stirred at room temperature for 24 h. The medium was then quenched with the addition of methanol (40 μ L) followed by a solution of HCl 10% (20 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in chloroform-d for ¹H NMR analysis.

Procedure for pinacolborane activated by alkoxide with cerium

To a solution of pinacolborane (7.0 mg, 54.9 μ mol) in THF (50 μ L) were added a solution of potassium *tert*butoxide (6.2 mg, 54.9 μ mol) in THF (100 μ L) and a solution of cerium (III) chloride (1.4 mg, 5.49 μ mol) in THF (50 μ L). After stirring at room temperature for 10 min, an epimeric mixture of sulfides **7** and **8** (4.0 mg, 11.0 μ mol) in solution in THF (100 μ L) was added to the medium. The reaction medium was stirred at room temperature for 24 h. The medium was then quenched with the addition of methanol (40 μ L) followed by a solution of HCl 10% (20 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in chloroform-d for ¹H NMR analysis.

Procedure for (+) and (-)-2-methyl-CBS-oxazoboroline with borane in THF

To a solution of CBS reagent (15.2 mg, 54.9 μ mol) in THF (150 μ L) was added a solution of borane-THF complex (1 M, 54.9 μ mol). After stirring at room temperature for 10 min, an epimeric mixture of sulfides **7** and **8** (4.0 mg, 11.0 μ mol) in solution in THF (150 μ L) was added to the medium. The reaction medium was stirred at room temperature for 24 h. The medium was then quenched with the addition of methanol (40 μ L) followed by a solution of HCl 10% (20 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in chloroform-d for ¹H NMR analysis.

Synthesis of 15-hydroxy-17-methylsulfinyl-*ent*-atisan-19-oic acids (1, 15-17) using different reducing reagents

<u>Procedure for neutral reducing reagents (diisobutylaluminum hydride, pinacolborane, borane in tetrahydrofuran)</u>

To a solution of **13** and **14** (2.0 mg, 5.26 μ mol) in THF (300 μ L) cooled down to 0°C was added reducing reagent (5 eq.). The reaction was stirred at cold temperature for 1h. The reaction was quenched by adding methanol (40 μ L) and a solution of HCl 10% (20 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in methanol-d₄ for ¹H NMR analysis. For ¹H and ¹³C NMR data of **1**, **15** and **16**, see **Supplementary Fig. S50-68**.

<u>Procedure for neutral reducing reagents (pinacolborane, borane in tetrahydrofuran) with Lewis acid</u> (cerium chloride)

To a solution of **13** and **14** (4.0 mg, 10.5 μ mol) in THF (300 μ L) was added a solution of Lewis acid (1.1 eq.) in THF (300 μ L) and stirred at room temperature for 1 h. After, the mixture was cooled down to 0°C and reducing reagent (5 eq.) was added. The reaction was stirred at cold temperature for 1h. The reaction was quenched by adding methanol (80 μ L) and a solution of HCl 10% (40 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in methanol-d₄ for ¹H NMR analysis.

Procedure for ionic reducing reagents (sodium borohydride)

To a solution of **13** and **14** (4.0 mg, 10.5 μ mol) in 200 proof ethanol (300 μ L) cooled down to 0°C was added a solution of sodium borohydride (4.0 mg, 105.1 μ mol) in 200 proof ethanol (300 μ L). The reaction was stirred at cold temperature for 45 min. The reaction was quenched by adding methanol (80 μ L) and a solution of HCl 10% (80 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in methanol-d₄ for ¹H NMR analysis.

Procedure for ionic reducing reagents (sodium borohydride) with Lewis acid (cerium chloride)

To a solution of **13** and **14** (4.0 mg, 10.5 μ mol) in 200 proof ethanol (300 μ L) was added a solution of cerium chloride (2.9 mg, 11.6 μ mol) in 200 proof ethanol (150 μ L) and stirred at room temperature for 1 h. After, the mixture was cooled down to 0°C and sodium borohydride was added (4.0 mg, 105.1 μ mol). The reaction was stirred at cold temperature for 45 min. The reaction was quenched by adding methanol (80 μ L) and a solution of HCl 10% (40 μ L). The mixture was concentrated and then diluted in a mixture of ethyl acetate and water. Once the layers separated, the organic phase was dried out. The residue was dissolved in methanol-d₄ for ¹H NMR analysis.






Fig. S1. Chemical synthesis of serofendic acids **1** from (-)-isosteviol **S1** from Terauchi et al.^{1,2} Reagents and conditions: **S1** to **2**, 8 steps, 13.4%; a) SeO₂, ^tBuOOH, CH₂Cl₂, r.t., 15 h, 28%; b) i. BH₃-THF, THF, r.t., 4 h, ii. NaOH aq., H₂O₂ aq., r.t., 2 h, 91%; c) NaBrO₃, NaHSO₃, CH₃CN, H₂O, r.t., 3 h, 80%; d) NaB(OAc)₃H, AcOH, CH₃CN, rt, 4 h, 73%; **3** to **1**, 3 steps, 50.9%.




Fig. S2. Chemical synthesis of serofendic acids **1** from 2-allylcyclohexanone **S5** from Toyota, et al.^{3,4} Reagents and conditions: **S5** to **S6**, 4 steps, 33.9%;³ **S6** to **2**, 8 steps, 15.4%; a) (PhSeO)₂O, benzene, reflux, 4 h, 80%; b) NaSMe aq., THF, r.t., 1 h; c) BH₃-THF, THF, 0°C; 1 h, 27% **4**, 27% **S10**, 18% **S11**, 18% **S12**; **4** to **1**, 2 steps, 80%.⁴

Fig. S3




Fig. S3. LC-MS analysis of the reaction between an epimeric mixture of 17-methylsulfenyl-15-oxo-*ent*atisan-19-oic acid **7** and **8** and different reducing reagents and different experimental conditions. Y-axis: i. (15R,16S)-15-hydroxy-17-methylsulfenyl-*ent*-atisan-19-oic acid **9** standard; ii. NaBH₄, EtOH, 0°C; iii. Lselectride, THF, 0°C; iv. NaBH(OAc)₃ (5 eq.), AcOH, CH₃CN, 0°C; v. NaBH(OAc)₃ (5 eq.), CH₃CN, 0°C; vi. NaBH(OAc)₃ (10 eq.), CH3CN, 0°C; vii. Disiamylborane, THF, 0°C.




Fig. S4. ¹H NMR analysis chloroform-d of the reaction between 17-methylsulfenyl-15-oxo-*ent*-atisan-19-oic acids **7** and **8** and activated pinacolborane in the presence or not of cerium (III) chloride. i. Reaction of **7** and **8** with activated HBpin; ii. Reaction of **7** and **8** with activated HBpin plus CeCl₃; iii.-vi. 15-hydroxy-17-methylsulfenyl-*ent*-atisan-19-oic acids standards (iii. **9**; iv. **10**, v. **11**, vi. **12**).




Fig. S5. ¹H NMR analysis in chloroform-d of the reaction between 17-methylsulfenyl-15-oxo-*ent*-atisan-19-oic acids **7** and **8** and 2-methyl-CBS-oxazaborolidines. i. Reaction of **7** and **8** with (+)-2- methyl-CBSoxazaborolidine; ii. Reaction of **7** and **8** with (-)-2- methyl-CBS-oxazaborolidine; iii.-vi. 15-hydroxy-17methylsulfenyl-*ent*-atisan-19-oic acids standards (iii. **12**; iv. **10**, v. **11**, vi. **9**); vii. **7** and **8**.




Fig. S6. ¹H NMR analysis in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and DiBAl-H. i. Reaction of **13** and **14** with DiBAl-H; ii.-vii. 15-hydroxy-17-methylsulfinyl*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.






Fig. S7. ¹H NMR spectrum in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and DiBAl-H. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:




Fig. S8. ¹H NMR analysis in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19oic acids **13** and **14** and DiBAl-H/CeCl₃. i. Reaction of **13** and **14** with DiBAl-H/CeCl₃; ii.-vii. 15-hydroxy-17methylsulfinyl-*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.






Fig. S9. ¹H NMR spectrum in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and DiBAl-H/CeCl₃. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:




Fig. S10. ¹H NMR analysis in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and DiBAl-H/ZnCl₂. i. Reaction of **13** and **14** with DiBAl-H/ZnCl₂; ii.-vii. 15-hydroxy-17-methylsulfinyl-*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.






Fig. S11. ¹H NMR spectrum in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and DiBAl-H/ZnCl₂. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:

% of cis = 100 *
$$\frac{integration of all cis methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$$

% of trans = 100 * $\frac{integration of all trans methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$
% of starting material = 100 * $\frac{integration of starting material methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$




Fig. S12. ¹H NMR analysis in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and HBpin. i. Reaction of **13** and **14** with HBpin; ii.-vii. 15-hydroxy-17-methylsulfinyl*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.




Fig. S13. ¹H NMR spectrum in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and HBpin. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:

% of cis = 100 *
$$\frac{integration of all cis methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$$

% of trans = 100 * $\frac{integration of all trans methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$
% of starting material = 100 * $\frac{integration of starting material methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$




Fig. S14. ¹H NMR analysis in methanol- d_4 of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and BH₃-THF. i. Reaction of **13** and **14** with BH₃-THF; ii.-vii. 15-hydroxy-17methylsulfinyl-*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.




Fig. S15. ¹H NMR spectrum in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and BH₃-THF. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:

% of cis = 100 *
$$\frac{integration of all cis methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$$

% of trans = 100 * $\frac{integration of all trans methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$
% of starting material = 100 * $\frac{integration of starting material methylsulfoxide peaks}{integration of all methylsulfoxide peaks}$




Fig. S16. ¹H NMR analysis in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and NaBH₄. i. Reaction of **13** and **14** with NaBH₄; ii.-vii. 15-hydroxy-17-methylsulfinyl-*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.

Fig. S17




Fig. S17. ¹H NMR spectrum in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and NaBH₄. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:




Fig. S18. ¹H NMR analysis in methanol-d₄ of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and NaBH₄/CeCl₃. i. Reaction of **13** and **14** with NaBH₄/CeCl₃; ii.-vii. 15-hydroxy-17methylsulfinyl-*ent*-atisan-19-oic acid standards (ii. **15B**; iii. **15A**; iv. mixture of **1A** and **1B**; v. **16B**; vi. **16A**; vii. mixture of **17A** and **17B**); viii. **13** and **14**.






Fig. S19. ¹H NMR spectrum in methanol- d_4 of the reaction between 17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acids **13** and **14** and NaBH₄/CeCl₃. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the methylsulfoxide group (chemical shifts: 2.654 ppm = *cis* **15A** and **16A**; 2.668 ppm = *cis* **15B** and **16B**; 2.676 ppm = *trans* **1A** and **17A**, 2.685 ppm = **13** and **14**and 2.692 ppm = *trans* **1B** and **17B**) of the different compounds in the sample. Assuming that all the starting material would be converted into products, we used the following formulas:




Fig. S20. ¹H NMR analysis in methanol-d₄ of the reaction between (16S,S)-17-methylsulfinyl-15-oxo-*ent*-atisan-19-oic acid **13B** and DiBAl-H/ZnCl₂. i. Reaction of **13B** with DiBAl-H/ZnCl₂; ii.-iii. 15-hydroxy-17-methylsulfinyl-*ent*-atisan-19-oic acid standards (ii. **1B**; iii. **15B**); vi. **13** and **14**.







Fig. S21. ¹H NMR spectrum in methanol-d₄ of the reaction between (16S,S)-17-methyl-sulfinyl-15-oxo-*ent*atisan-19-oic acid **13B** and DiBAl-H/ZnCl₂. The molar ratio between the reactants and the products was determined by using the integration of the peaks corresponding to the one of the protons of the C17methylene group (chemical shifts: 2.78 ppm = **15B**, 2.88 ppm = **1B** and 3.14 ppm =**13B**) of the different compounds in the sample. For the methylene of **13B**, as one part of the doublet of doublets is overlapping another peak (on the right in the spectrum), we doubled the value of the integration of the left part the doublet of doublet (0.17 x 2= 0.34). Assuming that all the starting material would be converted into products, we used the following formulas:

% of cis = 100 *
$$\frac{integration of methylene peak of 15B}{integration of all methylene peaks}$$


% of trans = 100 * $\frac{integration of methylene peak of 1B}{iintegration of all methylene peaks}$
% of starting material = 100 * $\frac{integration of methylene peak of 13B}{ntegration of all methylene peaks}$




ent-atis-16-en-19-oic acid (5)

Annotated NMR data for **5** in chloroform-*d*.

No.	δ ₊ (#H, mult., <i>J</i> (Hz))	δ_{c}
1	0.85 (1H, td, 3.3, 13.2)	39.6
	1.59 (1H <i>,</i> m)	
2	1.40 (1H, m)	18.8
	1.87 (1H, m)	
3	1.01 (1H, m)	38.3
	2.15 (1H, d, 14.0)	
4	-	43.9
5	1.05 (1H, dd, 1.5, 12.1)	57.2
6	1.75 (1H <i>,</i> m)	20.2
	1.82 (1H, m)	
7	1.11 (1H, m)	39.6
	1.47 (1H, td, 2.9, 13.2)	
8	-	33.6
9	1.13 (1H, m)	52.2
10	-	38.5
11	1.40 (1H, m)	28.7
	1.59 (1H <i>,</i> m)	
12	2.22 (1H, m)	36.6
13	1.54 (1H <i>,</i> m)	27.3
	1.60 (1H, m)	
14	1.00 (1H, m)	28.3
	1.97 (1H <i>,</i> m)	
15	1.88 (1H, d, 16.6)	48.3
	2.04 (1H, d, 16.6)	
16	-	152.6
17	4.56 (1H, d, 1.9)	104.7
	4.73 (1H, d, 1.9)	
18	0.90 (3H, s)	12.1
19	-	185.0
20	1.24 (3H, s)	29.0



Key COSY (bold) and HMBC (arrows) correlations



Key NOESY correlations




Fig. S23. ¹H spectrum of 5.

Fig. S24.





Fig. S24. ¹³C spectrum of 5.


Fig. S25.




ent-15-oxoatis-16-en-19-oic acid (6)

Annotated NMR data for **6** in chloroform-*d*

No.	δ _н (#H, mult., <i>J</i> (Hz))	δ _c
1	0.85 (1H, dd, 4.0, 13.5)	39.8
	1.62 (1H, m)	
2	1.42 (1H, m)	18.7
	1.86 (1H, m)	
3	1.02 (1H, m)	37.8
	2.17 (1H, d, 13.5)	
4	-	45.5
5	1.05 (1H, m)	56.3
6	1.84(1H, m)	19.6
	1.92 (1H, m)	
7	1.50 (1H, m)	30.1
	1.83 (1H, m)	
8	-	60.6
9	1.32 (1H, m)	46.7
10	-	39.3
11	1.57 (1H, m)	28.2
	1.71 (1H, m)	
12	2.76 (1H, m)	36.2
13	1.25 (1H, m)	24.8
	2.23 (1H, ddd, 3.2, 11.2,	
	14.3)	
14	1.72 (2H, m)	26.2
15	-	203.9
16	-	147.3
17	5.20 (1H, d, 1.3)	117.0
	5.94 (1H, d, 1.3)	
18	1.01 (3H, s)	12.8
19	-	182.6
20	1.27 (3H, s)	29.0



Key COSY (bold) and HMBC (arrows) correlations



Key NOESY correlations




Fig. S26.¹H spectrum of 6.





Fig. S27.¹³C spectrum of 6.


Fig. S28.




ent-(15S,16R)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (9)

Annotated NMR data for **9** in chloroform-d.

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ_{C}
1	0.88 (1H, m)	39.9
_	1.63 (1H, m)	
2	1.42 (1H, m)	18.9
2	1.85 (1H, m)	07 C
3	1.03 (1H, m)	37.6
	2.15 (1H, m)	42.0
4	-	43.8
5	1.08 (1H, m)	56.6
6	1.80 (2H, m)	19.7
7	1.12 (1H, dt, 2.7, 13.1)	33.2
	1.69 (1H <i>,</i> m)	
8	-	36.5
9	1.61 (1H, m)	47.4
10	-	38.1
11	1.48 (1H, m)	29.3
	1.53 (1H, m)	
12	1.66 (1H, m)	30.0
13	1.30 (1H, m)	21.3
	1.53 (1H, m)	
14	0.74 (1H, td, 6.5, 13.1)	27.5
	1.97 (1H <i>,</i> m)	
15	2.95 (1H, d, 3.7)	81.1
16	1.54 (1H, m)	42.1
17	2.53 (2H, d, 7.8)	39.3
18	0.91 (3H, s)	13.0
19	-	182.5
20	1.25 (3H, s)	29.0
21	2.14 (3H, s)	15.7
	· · · ·	



Key COSY (bold) and HMBC (arrows) correlations



Key NOESY correlations




Fig. S29.

Fig. S29. ¹H spectrum of 9.





Fig. S30.¹³C spectrum of 9 and 10.


Fig. S31.




ent-(15R,16R)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (10)

Annotated NMR data for **10** in chloroform-*d*.

No.	δ _н (#H, mult., <i>J</i> (Hz))	δ_{C}
1	0.88 (1H, m)	40.1
	1.63 (1H, m)	
2	1.41 (1H, m)	18.8
	1.87 (1H, m)	
3	1.02 (1H, m)	38.0
	2.15 (1H, m)	
4	-	43.8
5	1.02 (1H, m)	57.0
6	1.72 (1H, m)	20.1
	1.78 (1H, m)	
7	1.06 (1H, m)	37.6
	1.80	
8	-	35.6
9	0.99 (1H, m)	49.3
10	-	38.5
11	1.37 (1H, m)	29.3
	1.48 (1H, m)	
12	1.54 (1H, m)	30.4
13	1.27 (1H, m)	20.9
	1.64 (1H, m)	
14	1.47 (1H, m)	20.3
	1.64 (1H, m)	
15	3.45 (1H, d, 8.8)	77.8
16	1.97 (1H, m)	40.4
17	2.51 (1H, dd, 5.3, 12.2)	34.4
	2.89 (1H, m)	
18	0.94 (3H, s)	13.1
19	-	182.5
20	1.25 (3H, s)	29.0
21	2.14 (3H, s)	15.9



Key COSY (bold) and HMBC (arrows) correlations






Fig. S32. ¹H spectrum of 10.

Fig. S33.





Fig. S33.¹³C spectrum of 10.


Fig. S34.




ent-(15R,16S)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (11)

Annotated NMR data for **11** in chloroform-*d*.

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ_{C}
1	0.84 (1H <i>,</i> m)	39.9
	1.62 (1H, m)	
2	1.41 (1H, m)	18.8
-	1.87 (1H, m)	
3	1.01 (1H, m)	38.0
	2.16 (1H, m)	
4	-	43.8
5	1.02 (1H, m)	57.1
6	1.77 (2H, m)	20.0
7	1.03 (1H, m)	35.5
	1.70 (1H <i>,</i> m)	
8	-	36.2
9	0.86 (1H <i>,</i> m)	50.8
10	-	38.5
11	1.16 (1H, dd, 6.4,13.9)	22.8
	1.51 (1H <i>,</i> m)	
12	1.65 (1H <i>,</i> m)	29.3
13	1.47 (1H <i>,</i> m)	20.2
	1.66 (1H, m)	
14	1.47 (1H, m)	27.6
	1.58 (1H, m)	
15	2.92 (1H, dd, 1.7, 4.4)	84.4
16	1.61 (1H, m)	46.7
17	2.53 (2H, m)	39.1
18	0.92 (3H, s)	12.5
19	-	183.9
20	1.24 (3H, s)	29.0
21	2.13 (3H, s)	15.7



Key COSY (bold) and HMBC (arrows) correlations



Key NOESY correlations




Fig. S35. ¹H spectrum of 11.

Fig. S36.





Fig. S36.¹³C spectrum of 11.


Fig. S37.




ent-(15S,16S)-15-hydroxy-17-methylsulfenylatisan-19-oic acid (12)

Annotated NMR data for **12** in chloroform-*d*.

No.	δ _н (#H, mult. <i>, J</i> (Hz))	δ_{C}
1	0.92 (1H <i>,</i> m)	40.1
	1.58 (1H <i>,</i> m)	
2	1.40 (1H, m)	18.7
	1.80 (1H, m)	
3	1.01 (td, 4.2, 13.5, 17.6)	38.0
	2.14 (1H, m)	
4	-	43.9
5	1.10 (1H, m)	56.7
6	1.70 (1H, m)	20.0
	1.78 (1H, m)	
7	1.11 (1H, m)	34.0
	1.70 (1H, m)	
8	-	35.8
9	1.63 (1H, m)	41.7
10	-	38.2
11	1.1 (1H, m)	22.5
	1.63 (1H, m)	
12	1. 51 (1H, m)	31.3
13	1.47 (2H, m)	27.8
14	0.89 (1H <i>,</i> m)	26.9
	1.95 (1H <i>,</i> m)	
15	3.46 (1H, d, 8.8)	74.6
16	1.97 (1H, m)	40.1
17	2.51 (1H, dd, 4.8, 12.1)	34.9
	2.87 (t, 11.8)	
18	0.90 (3H, s)	12.7
19	-	184.4
20	1.23 (3H, s)	29.0
21	2.15 (3H, s)	15.8



Key COSY (bold) and HMBC (arrows) correlations



Key NOESY correlations




Fig. S38. ¹H spectrum of **12**.

Fig. S39.





Fig. S39.¹³C spectrum of 12.


Fig. S40.



ent-(16R,R)-17-methylsulfinyl-15-oxoatisan-19-oic acid (13B)

Annotated NMR data for **13B** in chloroform-*d*.

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ _c
1	0.88 (1H, m)	39.7
1	1.66 (1H, m)	55.7
2	1.44 (1H, m)	18.7
2	1.85 (1H, m)	10.7
3	1.03 (1H, m)	37.8
J	2.18 (1H, d_{app} , 13.3)	57.0
4	2.18 (11, d _{app} , 13.3)	43.7
4 5	- 1.02 (1H, m)	43.7 56.2
5 6	1.63 (1H, m)	21.1
0	1.74 (1H, m)	21.1
7		25.9
/	1.13 (1H, m)	25.9
0	2.30 (1H, m)	45.2
8		45.3
9	1.39 (1H, dd, 7.2, 11.0)	45.3
10	-	39.2
11	1.63 (1H, m)	28.2
	1.84 (1H, m)	
12	2.35 (1H, m)	30.9
13	1.73 (1H, m)	19.5
	1.84 (1H, m)	
14	1.50 (1H, m)	31.1
	1.68 (1H, m)	
15	-	216.9
16	2.78 (1H, m)	44.7
17	2.68 (1H, dd, 10.3, 13.0)	53.0
	3.18 (1H, dd, 3.6, 13.0)	
18	1.02 (3H, s)	13.0
19	-	182.4
20	1.25 (3H, s)	29.0
21	2.63 (3H, s)	38.8



Key NOESY correlations




Fig. S41. ¹H spectrum of 13B.

48







Fig. S42. ¹³C spectrum of **13B**.


Fig. S43.




ent-(16S,S)-17-methylsulfinyl-15-oxoatisan-19-oic acid (14A)

Annotated NMR data for **14A** in chloroform-*d*.

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ _c
1	0.82 (1H, td, 3.6, 13.1,	40.0
	16.9)	
	1.61 (1H, m)	
2	1.43 (1H, m)	18.8
	1.87 (1H, m)	
3	1.00 (1H, m)	38.0
	2.18 (1H, d _{app.} , 13.6)	
4	-	43.8
5	1.02 (1H, m)	56.3
6	1.76 (1H, m)	26.0
	1.88 (1H, m)	
7	1.36 (1H, m)	23.6
	2.24 (1H, m)	
8	-	45.3
9	1.17 (1H, dd, 6.8, 11.7)	47.9
10	-	39.6
11	1.49 (1H, m)	23.0
	1.72 (1H, m)	
12	2.33 (1H, m)	31.0
13	1.87 (2H, m)	19.4
14	1.40 (1H, m)	30.3
	1.82 (1H, m)	
15	-	216.8
16	2.82 (1H, m)	44.5
17	2.66 (1H, m)	53.0
	3.18 (1H, m)	
18	1.02 (3H, s)	12.7
19	-	182.3
20	1.25 (3H, s)	29.0
21	2.64 (3H, s)	38.9





Key NOESY correlations




Fig. S44. ¹H spectrum of 14A.

Fig. S45.




Fig. S45. ¹³C spectrum of 14A.

Fig. S46.





Fig. S46. ¹H-¹³C HMBC spectrum of **14A**


Fig. S47.




ent-(16S,R)-17-methylsulfinyl-15-oxoatisan-19-oic acid (14B)

Annotated NMR data for **14B** in chloroform-*d*.

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ _c
1	0.83 (1H, td, 4.1, 13.6,	39.9
-	17.3)	33.5
	1.61 (1H, m)	
2	1.42 (1H, m)	18.7
2	1.83 (1H, m)	10.7
3	1.00 (1H, m)	37.9
5	2.17 (1H, d _{app} , 13.6)	37.3
4	-	43.7
5	1.01 (1H, m)	56.3
6	1.39 (1H, m)	26.2
U	1.83 (1H, m)	20.2
7	1.33 (1H, m)	23.5
•	2.23 (1H, m)	20.0
8	-	45.3
9	1.17 (1H, dd, 6.5, 11.4)	47.8
10	-	39.6
11	1.46 (1H, m)	23.0
	1.80 (1H, m)	
12	2.34 (1H, m)	32.1
13	1.89 (2H, m)	19.4
14	1.75 (1H, m)	30.2
	1.80 (1H, m)	
15	-	216.9
16	2.68 (1H, m)	47.1
17	2.78 (1H, dd, 8.0, 13.3)	54.9
	3.06 (1H, dd, 4.8, 12.9)	
18	1.01 (3H, s)	12.7
19	-	181.4
20	1.24 (3H, s)	29.0
21	2.67 (3H, s)	40.0





Key NOESY correlations




Fig. S48. ¹H spectrum of 14B.





Fig. S49. ¹³C spectrum of 14B.


Fig. S50




ent-(15R,16R,S)-15-hydroxy-17-methylsulfinylatisan-19-oic acid (15A)

Annotated NMR data for **15A** in methanol- d_4

No.	δ _н (#H, mult., <i>J</i> (Hz))	δ_{c}
1	0.93 (1H, m)	41.3
	1.67 (1H, m)	
2	1.38 (1H, m)	20.0
	1.94 (1H <i>,</i> m)	
3	1.01 (1H, m)	39.2
	2.14 (1H, br. d, 13.2)	
4	-	44.6
5	1.00 (1H, m)	58.1
6	1.80 (2H, m)	21.2
7	1.03 (1H, m)	38.3
	1.71 (1H, m)	
8	-	36.7
9	1.06 (1H, m)	50.7
10	-	39.5
11	1.45 (1H <i>,</i> m)	30.1
	1.58 (1H, m)	
12	1.56 (1H <i>,</i> m)	32.6
13	1.34 (1H <i>,</i> m)	21.9
	1.67 (1H, m)	
14	1.48 (1H <i>,</i> m)	21.0
	1.67 (1H, m)	
15	3.39 (1H, m)	77.3
16	2.42 (1H, m)	37.7
17	2.54 (1H, dd, 4.0, 12.7)	57.1
	3.40 (1H <i>,</i> m)	
18	0.99 (3H, s)	13.6
19	-	181.5
20	1.17 (3H, s)	29.5
21	2.65 (3H, s)	38.7





Key NOESY correlations




Fig. S51. ¹H spectrum of 15A.

Fig. S52.






Fig. S52. ¹³C spectrum of 15A.




ent-(15R,16R,R)-15-hydroxy-17-methylsulfinylatisan-19-oic acid (15B)

Annotated NMR data for **15B** in methanol- d_4 .

No.	δ _н (#H, mult. <i>, J</i> (Hz))	δ _c
1	0.95 (1H <i>,</i> m)	41.3
	1.67 (1H, m)	
2	1.39 (1H, m)	20.0
	1.91 (1H, m)	
3	1.05 (1H, m)	39.1
	2.13 (1H, d, 13.1)	
4	-	44.6
5	1.05 (1H, m)	58.0
6	1.74-1.78 (2H, m)	21.3
7	1.08 (1H, m)	38.5
	1.75 (1H, m)	
8	-	36.7
9	1.08 (1H, m)	50.7
10	-	39.5
11	1.46 (1H, m)	29.9
	1.57 (1H, m)	
12	1.69 (1H, m)	31.1
13	1.34 (1H, m)	21.6
	1.68 (1H, m)	
14	1.49 (1H, m)	21.0
	1.66 (1H, m)	
15	3.36 (1H, d, 9.2)	78.1
16	2.33 (1H, m)	38.9
17	2.78 (1H, dd, 7.6, 13.2)	55.3
	3.29 (1H, dd, 7.6, 13.2)	
18	0.98 (3H, s)	13.6
19	-	181.6
20	1.20 (3H, s)	29.4
21	2.67 (3H, s)	38.5





Key NOESY correlations




Fig. S54. ¹H spectrum of 15B.

Fig. S55.





Fig. S55. ¹³C spectrum of **15B**.


Fig. S56.




Serofendic acid A (1A)

Annotated NMR data for **1A** in methanol- d_4 .

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ_{C}
1	0.88 (1H <i>,</i> m)	41.2
	1.62 (1H, m)	
2	1.38 (1H, m)	20.0
	1.89 (1H, m)	
3	1.03 (1H, m)	39.2
	2.13 (1H, d, 13.0)	
4	-	44.7
5	1.04 (1H, m)	57.9
6	1.79 (1H, m)	20.9
	1.86 (1H, m)	
7	1.07 (1H, m)	34.3
	1.71 (1H, m)	
8	-	37.7
9	1.57 (1H, m)	42.8
10	-	39.2
11	1.41 (1H, m)	30.0
	1.59 (1H, m)	
12	1.77 (1H, m)	32.2
13	1.38 (1H, m)	22.2
	1.64 (1H, m)	
14	0.83 (1H, m)	28.2
	2.02 (1H, ddd, 2.8, 11.8,	
	14.1)	
15	2.93 (1H, d, 4.4)	81.3
16	1.92 (1H, m)	44.4
17	2.83 (1H, dd, 6.1, 13.1)	60.9
	2.95 (1H, dd, 9.3, 13.1)	
18	0.95 (3H, s)	13.4
19	-	181.7
20	1.20 (3H, s)	29.6
21	2.68 (3H, s)	38.7



Key COSY (bold) and HMBC (arrows) correlations






Fig. S57. ¹H spectrum of **1A**.





Fig. S58. ¹³C spectrum of 1A.


Fig. S59.




Serofendic acid B (1B)

Annotated NMR data for **1B** in methanol- d_4 .

NIa	$S = (\# 1 + \pi \pi \pi) + \pi (1 + \pi)$	ç
No.	$\delta_{\rm H}$ (#H, mult., J(Hz))	$\delta_{\rm C}$
1	0.96 (1H, m)	41.3
	1.62 (1H, m)	
2	1.38 (1H, m)	20.1
	1.92 (1H, m)	
3	1.04 (1H, m)	39.4
	2.13 (1H, br. d, 13.2)	
4	-	44.3
5	1.04 (1H <i>,</i> m)	57.9
6	1.79 (1H, m)	21.0
	1.86 (1H, m)	
7	1.06 (1H, m)	34.3
	1.69 (1H, m)	
8	-	37.7
9	1.58 (1H, m)	42.9
10	-	39.2
11	1.42 (1H, m)	29.9
	1.59 (1H, m)	
12	1.75 (1H, m)	30.8
13	1.40 (1H, m)	21.9
	1.62 (1H, m)	
14	0.82 (1H, ddd, 6.2, 12.2,	28.4
	14.0)	
	2.04 (1H, ddd, 3.0, 11.7,	
	14.0)	
15	2.91 (1H, d, 4.4)	81.2
16	1.88 (1H, m)	44.3
17	2.88 (1H, dd, 9.3, 13.1)	59.8
	3.00 (1H, dd, 6.8,13.1)	
18	0.95 (3H, s)	13.5
19		181.0
20	1.19 (3H, s)	29.6
20	2.69 (3H, s)	38.3
Z T	2.03 (311, 3)	50.5



Key COSY (bold) and HMBC (arrows) correlations






Fig. S60. ¹H spectrum of **1B**.

Fig. S61.




Fig. S61. HSQC ¹H-¹³C spectrum of **1A** and **1B**.

Fig. S62.





Fig. S62. HMBC 1 H- 13 C spectrum of 1B.


Fig. S63.




ent-(15S,16S,S)-15-hydroxy-17-methylsulfinylatisan-19-oic acid (16A)

Annotated NMR data for **16A** in methanol- d_4 .

No.	δ ₊ (#H, mult., <i>J</i> (Hz))	δ_{c}
1	0.91 (1H, m)	41.0
	1.61 (1H, m)	
2	1.38 (1H, m)	20.0
	1.86 (1H, m)	
3	1.02 (1H, m)	39.4
	2.14 (1H, d _{app} , 13.5)	
4	-	44.7
5	1.03 (1H, m)	58.0
6	1.79 (1H <i>,</i> m)	21.1
	1.86 (1H, m)	
7	1.08 (1H, td, 2.9, 6.5, 12.9)	35.0
	1.62 (1H, m)	
8	-	37.2
9	1.63 (1H, m)	42.6
10	-	39.2
11	1.20 (1H, m)	23.3
	1.62 (1H, m)	
12	1.57 (1H <i>,</i> m)	33.3
13	1.52 (1H, m)	28.5
	1.58 (1H, m)	
14	0.96 (1H <i>,</i> m)	27.8
	2.00 (1H, m)	
15	3.37 (1H, d, 9.4)	74.4
16	2.44 (1H, m)	37.6
17	2.55 (1H, dd, 4.1, 12.8)	57.4
	3.40 (1H, dd, 11.4, 12.8)	
18	1.19 (3H, s)	29.5
19	-	181.0
20	0.94 (3H, s)	13.2
21	2.65 (3H, s)	38.7



Key COSY (bold) and HMBC (arrows) correlations








Fig. S64. ¹H spectrum of 16A.







Fig. S65. ¹³C spectrum of 16A.


Fig. S66.




ent-(15S,16S,R)-15-hydroxy-17-methylsulfinylatisan-19-oic acid (16B)

Annotated NMR data for **16B** in methanol- d_4 .

No.	δ _H (#H, mult., <i>J</i> (Hz))	δ _c
1	0.92 (1H, m)	41.0
	1.61 (1H, m)	
2	1.38 (1H, m)	20.0
	1.89 (1H, m)	
3	1.02 (1H, m)	39.2
	2.13 (1H, d _{app} , 13.3)	
4	-	44.7
5	1.05 (1H <i>,</i> m)	57.9
6	1.78 (1H, m)	21.1
	1.88 (1H, m)	
7	1.08 (1H, m)	35.0
	1.67 (1H, m)	
8	-	37.0
9	1.65 (1H <i>,</i> m)	42.6
10	-	39.4
11	1.56 (2H <i>,</i> m)	28.3
12	1.70 (1H <i>,</i> m)	31.9
13	1.20 (1H, m)	23.0
	1.64 (1H <i>,</i> m)	
14	0.96 (1H <i>,</i> m)	27.9
	2.00 (1H, m)	
15	3.34 (1H, d, 9.2)	75.1
16	2.34 (1H, m)	38.7
17	2.78 (1H, dd, 7.7, 13.3)	55.6
	3.28 (1H, dd, 7.6, 13.3)	
18	0.95 (3H, s)	13.2
19	-	181.7
20	1.19 (3H, s)	29.5
21	2.67 (3H, s)	38.5



Key COSY (bold) and HMBC (arrows) correlations






Fig. S67. ¹H spectrum of 16B.

- 75.12




Fig. S68. ¹³C spectrum of 16B.

- 1 T. Terauchi, N. Asai, Masahiro Yonaga, T. Kume, A. Akaike and H. Sugimoto, *Tetrahedron Lett.*, 2002, **43**, 3625–3628.
- T. Terauchi, N. Asai, T. Doko, R. Taguchi, O. Takenaka, H. Sakurai, M. Yonaga, T. Kimura, A. Kajiwara, T. Niidome, T. Kume, A. Akaike and H. Sugimoto, *Bioorg. Med. Chem.*, 2007, 15, 7098–7107.
- 3 M. Toyota, T. Wada and M. Ihara, J. Org. Chem., 2000, 65, 4565–4570.
- 4 M. Toyota, Takeshi Asano and M. Ihara, *Org. Lett.*, 2005, **7**, 3929–3932.